N-[2-(5-甲氧基-2-甲基-1H-吲哚-3-基)乙基]乙酰胺 | 68935-42-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[2-(5-甲氧基-2-甲基-1H-吲哚-3-基)乙基]乙酰胺
• 英文名称: N-[2-(5-methoxy-2-methyl-1H-indol-3-yl)ethyl]acetamide
• 英文别名: N-[2-(5-methoxy-2-methyl-indol-3-yl)-ethyl]-acetamide；2-methylmelatonin；Acetamide, N-(2-(5-methoxy-2-methyl-3-indolyl)ethyl)-
• CAS: 68935-42-2
• 化学式: C₁₄H₁₈N₂O₂
• 分子量: 246.309
• InChiKey: NWKYEVRJMWWEHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[2-(5-甲氧基-2-甲基-1H-吲哚-3-基)乙基]乙酰胺 、 对溴溴苄 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以30%的产率得到
  参考文献：
  名称：

  Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors

  摘要：

  Previous studies from our laboratory have revealed that esterification/amidation of the carboxylic acid moiety in the nonsteroidal anti-inflammatory drug, indomethacin, generates potent and selective COX-2 inhibitors. In the present study, a series of reverse ester/amide derivatives were synthesized and evaluated as selective COX-2 inhibitors. Most of the reverse esters/amides displayed time-dependent COX-2 inhibition with IC50 values in the low nanomolar range. Replacement of the 4-chlorobenzoyl group on the indole nitrogen with a 4-bromobenzyl moiety resulted in compounds that retained selective COX-2 inhibitory potency. In addition to inhibiting COX-2 activity in vitro, the reverse esters/amides also inhibited COX-2 activity in the mouse macrophage-like cell line, RAW264.7. Overall, this strategy broadens the scope of our previous methodology of neutralizing the carboxylic acid group in NSAIDs as a means of generating COX-2-selective inhibitors and is potentially applicable to other NSAIDs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.07.073
• 作为产物：
  描述：

  2-(5-甲氧基-2-甲基-1H-吲哚-3-基)乙酰胺 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 65.0h， 生成 N-[2-(5-甲氧基-2-甲基-1H-吲哚-3-基)乙基]乙酰胺
  参考文献：
  名称：

  Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors

  摘要：

  Previous studies from our laboratory have revealed that esterification/amidation of the carboxylic acid moiety in the nonsteroidal anti-inflammatory drug, indomethacin, generates potent and selective COX-2 inhibitors. In the present study, a series of reverse ester/amide derivatives were synthesized and evaluated as selective COX-2 inhibitors. Most of the reverse esters/amides displayed time-dependent COX-2 inhibition with IC50 values in the low nanomolar range. Replacement of the 4-chlorobenzoyl group on the indole nitrogen with a 4-bromobenzyl moiety resulted in compounds that retained selective COX-2 inhibitory potency. In addition to inhibiting COX-2 activity in vitro, the reverse esters/amides also inhibited COX-2 activity in the mouse macrophage-like cell line, RAW264.7. Overall, this strategy broadens the scope of our previous methodology of neutralizing the carboxylic acid group in NSAIDs as a means of generating COX-2-selective inhibitors and is potentially applicable to other NSAIDs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.07.073

文献信息

• Synthesis of Tryptamine Derivatives via a Direct, One-Pot Reductive Alkylation of Indoles
  作者：Marika Righi、Francesca Topi、Silvia Bartolucci、Annalida Bedini、Giovanni Piersanti、Gilberto Spadoni

  DOI：10.1021/jo3010028

  日期：2012.7.20

  An efficient, one-pot reductive alkylation of indoles with N-protected aminoethyl acetals in the presence of TES/TFA is reported. It represents the first general method for the direct synthesis of tryptamine derivatives from indoles and nitrogen-functionalized acetals. This convergent and versatile approach employs safe and inexpensive reagents, proceeds under mild conditions, and tolerates several

  报道了在TES / TFA存在下用N-保护的氨基乙基缩醛对吲哚进行有效的一锅还原烷基化反应。它代表了从吲哚和氮官能化的缩醛直接合成色胺的首个通用方法。这种融合和通用的方法使用安全且便宜的试剂，可在温和条件下进行，并可以耐受多个官能团。该新方法可有效地用于Luzindole（一种参考MT2选择性褪黑激素受体拮抗剂）和褪黑素的克级合成。
• Compounds effective in the treatment of circadian rhythms and related
  申请人：Instituto Farmacologico Lombardo-IFLO, S.a.S.

  公开号：US05552428A1

  公开（公告）日：1996-09-03

  The novel compounds of formula: ##STR1## in which R is isopropyl, cyclohexyl, phenyl, CH.sub.3, Br or I; or H R.sub.1 is CH.sub.3 or cyclopropyl and R.sub.2 is H or Br, and when R.sub.1 is cyclopropyl and R.sub.2 is H, R is other than H, and when R.sub.1 is CH.sub.3 and R.sub.2 is H, R is other than H, and when R.sub.1 is CH.sub.3 and R.sub.2 is H, R is other than I, and when R is CH.sub.3 and R.sub.2 is H, R.sub.1 is other than CH.sub.3, and when R is phenyl and R.sub.2 is H, R.sub.1 is other than CH.sub.3, exhibit superior activity in the treatment of pathologies which interfere with the circadian rhythm. A novel method of preparation is described according to which the pharmaceutical compositions containing the novel compounds, as well as compounds already known, are administered transdermally. The novel method of administration results in sustained peripheral blood level. Novel pharmaceutical compositions are described suitable for transdermal administration.

  该公式的新化合物为：##STR1##，其中R为异丙基、环己基、苯基、CH.sub.3、Br或I；或HR.sub.1为CH.sub.3或环丙基，R.sub.2为H或Br，当R.sub.1为环丙基且R.sub.2为H时，R不是H，当R.sub.1为CH.sub.3且R.sub.2为H时，R不是H，当R.sub.1为CH.sub.3且R.sub.2为H时，R不是I，当R为CH.sub.3且R.sub.2为H时，R.sub.1不是CH.sub.3，当R为苯基且R.sub.2为H时，R.sub.1不是CH.sub.3，表现出在干扰昼夜节律的病变治疗中具有优越活性。根据所述的一种新制备方法，含有新化合物的药物组合物以及已知的化合物经皮途径给药。新的给药方法导致持续的外周血药浓度水平。描述了适用于经皮给药的新型药物组合物。
• 2-Substituted 5-methoxy-N-acyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity
  作者：Gilberto Spadoni、Bojidar Stankov、Andrea Duranti、Gabriele Biella、Valeria Lucini、Americo Salvatori、Franco Fraschini

  DOI：10.1021/jm00077a010

  日期：1993.12

  was synthesized and their affinity for the melatonin receptor, isolated from whole quail brains, was tested in a succession of in vitro ligand-receptor binding experiments, using 2-[125I]iodomelatonin as a labeled ligand. Optimization of the C2 substituent and the N-acyl group resulted in compounds having picomolar affinity for the receptor (vs nanomolar affinity for melatonin). In two tests for evaluation

  合成了一系列的2-取代的5-甲氧基-N-酰基草胺，并使用2- [125I]碘酮在一系列体外配体-受体结合实验中测试了它们与从鹌鹑全脑分离的褪黑激素受体的亲和力。作为标记的配体。C2取代基和N-酰基的最优化产生对受体具有皮摩尔亲和力的化合物（对褪黑激素具有纳摩尔亲和力的化合物）。在两项评估生物学活性的测试中（对兔顶叶皮层中单个神经元的自发放电活性的影响，以及体内的叙利亚仓鼠性腺回归模型），大多数类似物均起激动剂的作用。单独在C2处进行异丙基取代，或在N-酰基位置上同时进行环丙基取代，会导致亲和力低得多，且生物学作用较弱，或在后一种情况下缺乏活动。令人感兴趣的是化合物4d（R =苯基，R1 = CH3）和4g（R =苯基，R1 =环丙基），尽管使用类似物，但在所用实验模型的条件下对受体具有很高的亲和力并具有明显的拮抗活性。 4 g（R =苯基，（R1 =环丙基）似乎是一种弱拮抗剂，并且在较高浓
• Percutaneous absorption preparation
  申请人：Suzuki Yasuyuki

  公开号：US20090264521A1

  公开（公告）日：2009-10-22

  Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night.

  经皮吸收制剂可以通过方便的给药系统吸收具有褪黑素受体激动剂活性的化合物，具有良好的血药浓度时间曲线，并可以对由于夜间褪黑素分泌减少而引起的疾病产生治疗效果。
• PERCUTANEOUS ABSORPTION PREPARATIONS
  申请人：SUZUKI Yasuyuki

  公开号：US20120309823A1

  公开（公告）日：2012-12-06

  Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night.

  经皮吸收制剂使得通过便捷的给药系统吸收具有褪黑素受体激动剂活性的化合物成为可能，具有良好的血药浓度-时间曲线，并且可以对由夜间褪黑素分泌减少引起的疾病产生治疗效果。